OncoMatch/Clinical Trials/NCT05698524
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Is NCT05698524 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including PCI 24781 and Temozolomide for recurrent high grade glioma.
Treatment: PCI 24781 · Temozolomide — Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standard therapy, radiation therapy and chemotherapy with temozolomide, few options are available. Even with further therapy, median progression free survival at 6 months after first relapse (PFS-6) is only 15%. Similarly, anaplastic astrocytoma and anaplastic oligodendroglioma, grade III gliomas, once recurrent after radiation therapy and first-line chemotherapy, have identical therapeutic options and poor outcomes with PFS-6 of 31%. Temozolomide (TMZ) has a favorable side effect profile and is available orally, however, cytotoxicity occurs. Metronomic temozolomide at low doses on a continuous schedule, have demonstrated better survival in studies. This study will determine the recommended dose and the side effects of PCI-24781/Abexinostat with metronomic temozolomide.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage III, IV (WHO grade)
Grade: IIIIV (WHO)
high grade (aka grade III or IV) glioma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy
Prior radiation therapy
Must have received: cytotoxic chemotherapy (temozolomide) — standard
standard temozolomide
Lab requirements
Blood counts
ANC count ≥1,500/mm3, hemoglobin > 8 g/dL, platelet count ≥100,000/mm3
Kidney function
serum creatinine that is at or below 2.0 mg/dL
Liver function
serum AST and ALT less than 1.5 times the upper limits of normal, serum alkaline phosphatase less than 2.5 times the upper limits of normal
Adequate bone marrow reserve (ANC count ≥1,500/mm3, hemoglobin > 8 g/dL, platelet count ≥100,000/mm3); Adequate renal function (a serum creatinine that is at or below 2.0 mg/dL); Adequate hepatic function (serum AST and ALT less than 1.5 times the upper limits of normal, serum alkaline phosphatase less than 2.5 times the upper limits of normal)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Nebraska Medical Center · Omaha, Nebraska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify